Edition:
India

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

10.71USD
2:29am IST
Change (% chg)

$0.14 (+1.32%)
Prev Close
$10.57
Open
$10.57
Day's High
$10.82
Day's Low
$10.50
Volume
436,074
Avg. Vol
1,223,133
52-wk High
$18.50
52-wk Low
$5.28

Latest Key Developments (Source: Significant Developments)

Endo Agrees Not To Oppose Additional Stay Of FDA Litigation Following Restoration Of Government Appropriations
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Endo International PLC ::ENDO AGREES NOT TO OPPOSE ADDITIONAL STAY OF FDA LITIGATION FOLLOWING RESTORATION OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL - U.S. FDA HAS REQUESTED A FURTHER STAY OF ENDO'S ONGOING LITIGATION AGAINST FDA THROUGH MARCH 15, 2019.  Full Article

Endo Agrees Not To Oppose Additional Stay Of FDA Litigation Following Restoration Of Govt Appropriations
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Endo International PLC ::ENDO AGREES NOT TO OPPOSE ADDITIONAL STAY OF FDA LITIGATION FOLLOWING RESTORATION OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL PLC - FDA REQUESTED A FURTHER STAY OF ENDO'S ONGOING LITIGATION AGAINST FDA THROUGH MARCH 15, 2019.ENDO INTERNATIONAL - IN STAY MOTION FDA "EXPECTS TO PUBLISH FINAL CLINICAL NEED DETERMINATION FOR VASOPRESSIN ON OR BEFORE MARCH 15, 2019.".  Full Article

Endo Anticipates Further Stay Of Compounding Litigation Due To Lapse Of Govt Appropriations
Monday, 31 Dec 2018 

Dec 31 (Reuters) - Endo International PLC ::ENDO ANNOUNCES ANTICIPATED FURTHER STAY OF COMPOUNDING LITIGATION DUE TO LAPSE OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL PLC - FDA FILED A MOTION, SEEKING A FURTHER STAY OF SUIT FOR PERIOD OF TIME IN WHICH GOVERNMENT LACKS APPROPRIATIONS.ENDO INTERNATIONAL PLC - ENDO, OTHER INTERESTED PARTIES HAVE SUBMITTED COMMENTS ON FDA'S PROPOSED VASOPRESSIN DETERMINATION.ENDO INTERNATIONAL - IN LIGHT OF APPROPRIATIONS LAPSE, PROPOSED VASOPRESSIN DETERMINATION WILL NOW NOT OCCUR BY DEC 31, 2018.ENDO INTERNATIONAL PLC - IF FDA'S MOTION IS GRANTED, LITIGATION WILL BE STAYED FOR AS LONG AS APPROPRIATIONS LAPSE CONTINUES.ENDO INTERNATIONAL PLC - IS NOT AT THIS TIME AWARE WHEN APPROPRIATIONS MAY RESUME.  Full Article

Catalyst Pharmaceuticals Announces Definitive Agreement With Endo For Vigabatrin Tablets
Tuesday, 18 Dec 2018 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES DEFINITIVE AGREEMENT WITH ENDO FOR VIGABATRIN TABLETS.CATALYST PHARMACEUTICALS INC - WILL RECEIVE AN UP-FRONT PAYMENT, MILESTONE PAYMENTS BASED ON ACHIEVEMENT OF REGULATORY APPROVALS.CATALYST PHARMACEUTICALS INC - UNDER DEAL, CO TO ALSO RECEIVE SHARING OF DEFINED NET PROFITS UPON COMMERCIALIZATION.CATALYST PHARMACEUTICALS - SIGNED AGREEMENT WITH ENDO INTERNATIONAL'S UNIT FOR FURTHER DEVELOPMENT,COMMERCIALIZATION OF GENERIC SABRIL TABLETS.  Full Article

Endo International Says Timing Of Launch For Cellulite Treatment CCH Will Be Second Half Of 2020
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Endo International PLC ::SAYS EXPECTS TO SUBMIT MARKETING APPLICATION FOR CELLULITE TREATMENT CCH IN SECOND HALF OF 2019 - CONF. CALL.SAYS TIMING OF LAUNCH FOR CELLULITE TREATMENT CCH WILL BE SECOND HALF OF 2020- CONF. CALL.  Full Article

Endo International Q3 Revenues Of $745 Million
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC Q3 REVENUES OF $745 MILLION VERSUS $787 MILLION.ENDO INTERNATIONAL PLC QTRLY REPORTED DILUTED LOSS PER SHARE FROM CONTINUING OPERATIONS OF $0.65.ENDO INTERNATIONAL PLC QTRLY ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS OF $0.71.ENDO INTERNATIONAL PLC SEES FY 2018 TOTAL REVENUES BETWEEN $2.87 BILLION AND $2.92 BILLION.  Full Article

Endo Q3 Adjusted EPS $0.71 From Continuing Operations
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Endo International PLC ::ENDO REPORTS THIRD-QUARTER 2018 FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.71 FROM CONTINUING OPERATIONS.Q3 GAAP LOSS PER SHARE $0.65 FROM CONTINUING OPERATIONS.Q3 REVENUE $745 MILLION VERSUS I/B/E/S VIEW $694.9 MILLION.Q3 EARNINGS PER SHARE VIEW $0.59 -- THOMSON REUTERS I/B/E/S.RAISES 2018 FINANCIAL GUIDANCE.NOW SEES FY 2018 TOTAL REVENUE $2.87 BILLION TO $2.92 BILLION; ADJUSTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS BETWEEN $2.65 AND $2.75.FY2018 EARNINGS PER SHARE VIEW $2.60, REVENUE VIEW $2.81 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Endo Announces Positive Results From Phase 3 Studies Of Collagenase Clostridium Histolyticum
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Endo International PLC ::ENDO ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDIES OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) IN PATIENTS WITH CELLULITE.ENDO INTERNATIONAL PLC - CCH WAS WELL-TOLERATED IN ACTIVELY-TREATED SUBJECTS.ENDO INTERNATIONAL - BOTH RELEASE-1 AND RELEASE-2 STUDIES DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT RESULTS ON EFFICACY ENDPOINTS.ENDO INTERNATIONAL PLC - ANNOUNCED POSITIVE RESULTS TODAY FROM TWO IDENTICAL PHASE 3 RELEASE* STUDIES OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.  Full Article

Par Pharm Inc Wins FDA's Tentative Approval For Topiramate
Tuesday, 25 Sep 2018 

Sept 24 (Reuters) - Endo International PLC ::PAR PHARM INC WINS FDA'S TENTATIVE APPROVAL FOR TOPIRAMATE - FDA WEBSITE.  Full Article

Endo Agrees To Additional Stay In Litigation Case Against U.S. FDA
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Endo International PLC ::ENDO AGREES TO ADDITIONAL STAY OF FDA LITIGATION FOLLOWING FDA'S COMMITMENT TO USE BEST EFFORTS TO FINALIZE VASOPRESSIN CLINICAL NEED DETERMINATION BY YEAR END.ENDO INTERNATIONAL PLC - AGREED TO AN ADDITIONAL STAY OF ITS LITIGATION AGAINST U.S. FDA UNTIL DECEMBER 31, 2018.ENDO INTERNATIONAL PLC - ENDO AGREED TO PROPOSED STAY AND PARTIES JOINTLY MOVED COURT FOR APPROVAL ON SEPT 21, 2018.ENDO INTERNATIONAL SAYS MOTION WAS UNOPPOSED BY INTERVENOR OUTSOURCING FACILITY.ENDO INTERNATIONAL - IF COURT APPROVES PROPOSED STAY CO'S MOTION FOR PRELIM INJUNCTION TO BE HELD IN ABEYANCE.ENDO INTERNATIONAL PLC - REITERATES PRIOR STATEMENT THAT BULK COMPOUNDING OF VASOPRESSIN BY OUTSOURCING FACILITIES IS "INAPPROPRIATE".ENDO INTERNATIONAL - HEARING ON MOTION FOR PRELIM INJUNCTION CURRENTLY SCHEDULED FOR OCTOBER 3, 2018 WILL BE TAKEN OFF CALENDAR.  Full Article